COEP
Coeptis Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.99
−8.57%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
—
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Feb 13, 2026 | Cogley Brian · officer: Chief Financial Officer | M-Exempt | 10,000 | $11 |
| Feb 13, 2026 | Cogley Brian · officer: Chief Financial Officer | A-Award | 12,500 | $0.00 |
| Feb 13, 2026 | Deschamps Philippe · director | M-Exempt | 5,700 | $11 |
| Feb 13, 2026 | Deschamps Philippe · director | A-Award | 3,250 | $0.00 |
| Feb 13, 2026 | Calise Chris · director | M-Exempt | 5,700 | $11 |
| Feb 13, 2026 | Calise Chris · director | A-Award | 3,250 | $0.00 |
| Feb 13, 2026 | Mehalick David · director, 10 percent owner, officer: CEO and President | M-Exempt | 148,875 | $7.05 |
| Feb 13, 2026 | Mehalick David · director, 10 percent owner, officer: CEO and President | A-Award | 51,250 | $0.00 |
| Feb 13, 2026 | Cochran Christopher P. · director | M-Exempt | 5,700 | $11 |
| Feb 13, 2026 | Cochran Christopher P. · director | A-Award | 3,250 | $0.00 |
| Feb 13, 2026 | Yerace Daniel Alexander · director, officer: VP Operations | M-Exempt | 10,000 | $10 |
| Feb 13, 2026 | Yerace Daniel Alexander · director, officer: VP Operations | A-Award | 20,000 | $0.00 |
| Feb 13, 2026 | Salkind Gene · director | M-Exempt | 5,700 | $11 |
| Feb 13, 2026 | Salkind Gene · director | A-Award | 3,250 | $0.00 |
| Feb 13, 2026 | DeSilva Tara · director | M-Exempt | 5,700 | $11 |
| Feb 13, 2026 | DeSilva Tara · director | A-Award | 3,250 | $0.00 |
| Feb 13, 2026 | Sheehy Christine Elise · officer: VP Compliance and Secy | M-Exempt | 1,000 | $11 |
| Feb 13, 2026 | Sheehy Christine Elise · officer: VP Compliance and Secy | A-Award | 12,500 | $0.00 |
| Mar 10, 2025 | Deschamps Philippe · director | A-Award | 5,700 | $11 |
| Mar 6, 2025 | Cogley Brian · officer: Chief Financial Officer | A-Award | 10,000 | $11 |
| Mar 6, 2025 | Yerace Daniel Alexander · director, officer: VP of Operations | A-Award | 5,000 | $11 |
| Mar 6, 2025 | Sheehy Christine Elise · officer: VP Compliance and Secy | A-Award | 1,000 | $11 |
| Mar 6, 2025 | Salkind Gene · director | A-Award | 5,700 | $11 |
| Mar 6, 2025 | Mehalick David · director, 10 percent owner, officer: CEO and President | A-Award | 28,875 | $11 |
| Mar 6, 2025 | DeSilva Tara · director | A-Award | 5,700 | $11 |
| Mar 6, 2025 | Cochran Christopher P. · director | A-Award | 5,700 | $11 |
| Mar 6, 2025 | Calise Chris · director | A-Award | 5,700 | $11 |
| Jan 17, 2024 | Cogley Brian · officer: Chief Financial Officer | Purchase | 5,000 | $0.67 |
| Jan 16, 2024 | DeSilva Tara · director | Purchase | 1,800 | $0.58 |
| Jan 16, 2024 | DeSilva Tara · director | Purchase | 466 | $0.56 |
Institutional positioning
13F filings over the trailing two quarters
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ANCHOR INVESTMENT MANAGEMENT, LLC | Unchanged | 7,000 | May 1, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Feb 13, 2026